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Background: A left ventricular assist device (LVAD) is normally contraindicated in signiﬁcant
aortic regurgitation (AR) and requires intraoperative valve repair or exclusion. Nevertheless,
AR  can coexist with an LVAD, so a valid question when asked might still be of clinical sig-
niﬁcance. The purpose of this study is to analyze the effects of valve regurgitation on the
pumping efﬁcacy of continuous and pulsatile LVADs with a computational method.
Methods: A cardiovascular model was developed based on the Windkessel model, which
reﬂects the hemodynamic ﬂow resistance and the blood wall elasticity. Using the Windkessel
model, important cardiovascular components, such as the right atrium, right ventricle, pul-
monary artery, pulmonary vein, left atrium (LA), left ventricle (LV), aorta, and branching
blood vessels, were expressed.
Results: In the case of AR, continuous and pulsatile LVADs improved cardiac output and
reduced mechanical load slightly. In the case of mitral regurgitation, the LVADs improved
cardiac output (cardiac outputs were about 5 L/min regardless of the severity of regurgitation)
and reduced afterload signiﬁcantly.Conclusion: AR reduced both continuous and pulsatile LVAD function signiﬁcantly while
mitral regurgitation did not affect their pumping efﬁcacy.
© 2016 Korea Institute of Oriental Medicine. Published by Elsevier. This is an open access
article under the CC BY-NC-ND license∗ Corresponding author. Department of Medical IT Convergence Engin
Gumi, Gyeongbuk 730-701, Korea.
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Fig. 1 – Schematic drawing of the cardiovascular system
model that consists of eight compartments. See Lim et al15
for the detailed parameter information.
SF, scale factor for the leakage resistance.
partments, each of which is expressed as Eq. (1), Eq. (2), and.S. Kim et al/VR Effects on CLVAD and PLVAD Pumping Efﬁcacy 
.  Introduction
 left ventricular assist device (LVAD) is an electromechanical
evice used to replace part of the function of a failed heart, by
elping to circulate blood through the body. Recently, LVADs
ave been used as a bridge to transplantation1 or destina-
ion therapy.2,3 Valve regurgitation, i.e., backward ﬂow in the
eart when a cardiac valve does not completely close, has been
ound to have a signiﬁcant effect on cardiac function.4 Heart
alves are located between the atria and the ventricles (the
itral and tricuspid valves), and between the ventricles and
he aortas (the aortic and pulmonary aortic valves). Cardiac
esponses, such as cardiac output and blood pressure, vary
ccording to which valve is affected and the severity of regur-
itation. Valve regurgitation also affects the LVAD pumping
fﬁcacy differently following LVAD therapy.5,6 LVAD is nor-
ally contraindicated in signiﬁcant aortic regurgitation (AR)
nd requires intraoperative valve repair or exclusion.7,8 Fur-
hermore, LVAD aggravates preexisting AR.9,10 Nevertheless,
R can coexist with LVAD,11 so a valid question when asked
ight still be of clinical signiﬁcance.
While much research has focused on determining regur-
itation volume using medical imaging techniques, and also
redicting the effects of regurgitant volume on ventricular
echanical function,12,13 no study has focused on predicting
he effects of regurgitation severity in speciﬁc valvular regurgi-
ation on LVAD function in the failed ventricle following LVAD
herapy.
The pumping efﬁcacy of LVADs according to the severity of
alvular insufﬁciency can be investigated in animal and clini-
al studies. However, experimental methods to document and
valuate cardiac responses in detail, such as the ventricular
nloading effect of LVAD, are hampered by low spatiotempo-
al resolution. As an alternative, computational methods can
e applied. We  have performed several studies comparing ven-
ricular unloading effects under different pumping types14,15
nd cannulation sites16 using computational methods.
We used a previously developed computational model of
he cardiovascular system to analyze the effects of aortic and
itral valve regurgitation on the pumping efﬁcacy of contin-
ous and pulsatile LVADs.
.  Methods
.1.  Cardiovascular  model
s shown in Fig. 1, the cardiovascular model was developed
ased on the Windkessel model, which reﬂects the hemody-
amic ﬂow resistance and the blood wall elasticity.17 Dynamic
arameters, such as ﬂow resistance and blood wall elastic-
ty, were expressed as the electric resistance and the electric
ompliance components, which are linear electric circuit ele-
ents. Using the Windkessel model, important cardiovascular
omponents, such as the right atrium, right ventricle, pul-
onary artery, pulmonary vein, left atrium (LA), left ventricle
LV), aorta, and branching blood vessels, were expressed.
The heart spontaneously contracts and relaxes repeatedly
hrough electrical signals, action potentials, to change itselasticity, which is a dynamic material property. Consider-
ing these features, the time-varying compliance suggested by
Suga and Sagawa17 was used in this study, unlike other lin-
ear capacitors (Fig. 2). The LVAD was assumed to be a ﬂow
generator that continuously ejects blood, and was connected
in parallel to the LV and the aorta, as shown in Fig. 1. The
cardiovascular model is composed of eight Windkessel com-Fig. 2 – Time-varying compliance of the right and left
ventricles.
HF, heart failure; NORM, normal condition.
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Fig. 3 – Left ventricular assist device (LVAD) ﬂow rate for
one pumping cycle.
Dashed line, pulsatile LVAD (PLVAD) inﬂow; dotted line,
continuous LVAD (CLVAD) inﬂow and outﬂow; solid line,24  
Eq. (3) based on Poiseuille’s law, mass balance law, and Hooke’s
law, respectively.
Qi =
pi(t) − pi−1(t)
R1
(1)
dVt(t)
dt
= Qin,i(t) − Qout,i(t) (2)
pi(t) − pex,i(t) +
Vi(t) − Vun,i(t)
Ci
(3)
Here, i represents the compartment index, V the blood vol-
ume, Qin the blood inﬂow rate, Qout the blood ﬂow rate, P the
internal blood vessel pressure, Pex the external blood vessel
pressure, C the blood vessel or heart wall compliance, and Vun
the volume when the pressure in the blood vessels differs from
that outside.
2.2.  Heart  failure  and  valvular  insufﬁciency  condition
To mimic  spontaneous pumping of the heart, time-varying
compliance was used for the model in this study. This is an
equation for the internal pressure and volume of the pul-
sating heart. Several previous cardiovascular hemodynamic
studies simulated the heart using this time-varying compli-
ance concept.15,18,19 Fig. 2 shows the ventricular time-varying
compliance of a normal individual and a patient with sug-
gested heart failure. A heart failure model was implemented
by increasing the end-systolic compliance value to 2.5× nor-
mal. This produced hemodynamic results that were consistent
with data reported for systolic heart failure patients in previ-
ous clinical studies.14,20
To simulate the valve regurgitation caused by mitral and
aortic valve insufﬁciency, one further route was added to the
aortic and mitral valve compartment for regurgitation (see for-
ward diodes and back diodes next to RPV and RLV in Fig. 1).
There were forward and reverse diodes, which had different
resistance components. The hemodynamic phenomena with
the mitral and aortic valve insufﬁciency are expressed as fol-
lows:
QMI =
⎧⎪⎨
⎪⎩
PLA − PLV
RMI
when PLA > PLV
PLA − PLV
RMI,Leak
= PLA − PLV
RMI
× SF
100
when PLA ≤ PLV
(4)
QAO =
⎧⎪⎨
⎪⎩
PLV − PAO
RAO
when PLV > PAO
PLV − PAO
RAO,Leak
= PLV − PAO
RAO
× SF
100
when PLV ≤ PAO
(5)
Here, QMI represents the left mitral valve inﬂow rate, PLA
the LA pressure, PLV the LV pressure, RMI the forward ﬂow
resistance through the mitral valve, RMI.Leak the leakage ﬂow
resistance through the mitral valve, QAO the forward ﬂow
through the aortic valve, PAO the aortic blood pressure, RAO
the forward ﬂow resistance through the aortic valve, and
RAO.Leak the leakage ﬂow resistance through the aortic valve.
SF is a scale factor that expresses the severity of regurgita-
tion through the valve. SF was increased from 0% to 10% inPLVAD outﬂow.
2% increments. SF = 0% indicates that the valve is completely
closed when PLV > PLA, or when PLV < PAO, and SF = 10% indi-
cates that the valve is not completely closed, so ∼10% of
the ﬂow, which is estimated by Poiseuille’s law with a given
pressure difference, is regurgitated. According to our previous
research,21 regurgitant volumes were saturated from SF 10%.
That is why we set the range of the SF value from 0% to 10%.
2.3.  Simulation  method
Simulations were conducted for the case without valvular
insufﬁciency and the ﬁve different mitral valvular and aortic
valvular insufﬁciency conditions with use of the continuous
LVAD (CLVAD) and the pulsatile LVAD (PLVAD). To mimic  the
universal LVAD ﬂow, the mean ﬂow rate (5 L/min) was set for
the CLVAD, and the cosine wave  function that generated a
mean ﬂow rate identical to that of the CLVAD was used for the
PLVAD. Fig. 3 shows the rates of inlet ﬂow to the LVAD and the
outlet ﬂow from the LVAD. In the PLVAD, the counter-pulsation
method4,5, which was shown to be the optimal pulsation con-
dition for improving the ventricular afterload, decreased and
the coronary circulation was used. The LVAD intubation was
connected to the aorta in parallel to the LV. The regurgitation
levels, indicated as SF in Eqs. (4) and (5), in the aortic and mitral
valves, were set at 0%, 2%, 4%, 6%, 8%, and 10%, and simula-
tions were conducted using the two types of LVAD according
to the regurgitation level.
3.  Results
Fig. 4 shows the LV and aortic blood pressures in the case of
aortic valvular insufﬁciency without LVAD treatment (Fig. 4A)
and with CLVAD (Fig. 4B) and PLVAD (Fig. 4C) treatment. With-
out LVAD treatment, more  severe aortic valvular regurgitation
resulted in increases in ventricular and aortic systolic blood
pressures, and a decrease in the aortic diastolic pressure.
Without LVAD treatment, when aortic valvular insufﬁciency
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Fig. 4 – Left ventricular and aortic pressure proﬁles under
the aortic valve regurgitation. (A) Without left ventricular
assist device (LVAD) treatment. (B) With continuous LVAD
(CLVAD) treatment. (C) With pulsatile LVAD (PLVAD)
treatment.
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Fig. 5 – Left ventricular and aortic pressure proﬁles under
the mitral valve regurgitation. (A) Without left ventricular
assist device (LVAD) treatment. (B) With continuous LVAD
(CLVAD) treatment. (C) With pulsatile LVAD (PLVAD)
treatment.
MR,  mitral regurgitation.R, aortic regurgitation.
eveloped, the amount of blood from the LA to the LV
as normal, but the blood ejected to the aorta ﬂowed back
o the LV. Consequently, the systolic LV and aortic blood
ressures increased with increases in severity of regurgita-
ion, the mean arterial blood pressure decreased (48 mmHg
nder 10% AR condition), and the difference between the
ean LV blood pressure and the mean aortic blood pressure
ecreased (Fig. 4A). As the LVAD helped the LV pump blood, the
ean arterial blood pressure remained higher than without
VAD treatment, and the LV systolic blood pressure decreased
ventricular pressure unloading). In Fig. 4B and 4C, the mean
rterial blood pressure decreased with increasing severity of
egurgitation in the case of aortic valvular insufﬁciency with
LVAD or PLVAD treatments. The aortic blood pressure was
lightly lower than that in the absence of LVAD treatment
Fig. 4B and 4C). Accordingly, the increase in arterial bloodpressure, which is a major function of LVAD, was inhibited
(Fig. 4A–C).
Fig. 5 shows the LV and aortic blood pressures in the case of
mitral valvular insufﬁciency without LVAD treatment (Fig. 5A)
and with CLVAD (Fig. 5B) or PLVAD (Fig. 5C) treatment. The
mitral valve regurgitation resulted in decreases in LV and
aortic systolic blood pressures with increases in severity of
regurgitation (72 mmHg  of mean arterial pressure under 10%
mitral regurgitation (MR) severity). In the case of mitral valvu-
lar insufﬁciency without LVAD treatment, the blood from the
LA to the LV ﬂowed back to the LA. With more  severe regur-
gitation, the ﬂow of blood ejected to the aorta decreased,
which also decreased the aortic blood pressure (Fig. 5A).
With CLVAD and PLVAD treatments, the arterial mean blood
pressure remained high regardless of the severity of regurgi-
tation (Fig. 5B and 5C). Mean arterial pressure was 98 mmHg
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Fig. 6 – Pressure-volume loops under the aortic and mitral valve regurgitation conditions (A and B) without left ventricular
assist device (LVAD) treatment, (C and D) with continuous LVAD (CLVAD) treatment, and (E and F) with pulsatile LVAD
(PLVAD) treatment.
AR, aortic regurgitation; MR,  mitral regurgitation.
with CLVAD treatment and 97 mmHg  with PLVAD treatment.
Accordingly, it was conﬁrmed that the arterial blood pres-
sure increased and the ventricular load decreased with LVAD
treatment (Fig. 5A–C). With PLVAD treatment, the ventricular
systolic blood pressure decreased with more  severe valvu-
lar regurgitation, and became lower than that with CLVAD
treatment (Fig. 5C). LV peak pressure (LVPP) was 48 mmHg
with CLVAD and 30 mmHg  with PLVAD. Accordingly, PLVAD
treatment was more  effective than CLVAD treatment under
conditions of mitral regurgitation in terms of the ventricular
pressure unloading effect.Fig. 6 shows the LV pressure-volume graph according to
the severity of aortic valvular insufﬁciency and mitral valvular
insufﬁciency under conditions of CLVAD and PLVAD treat-
ment. Without LVAD treatment, the end-diastolic volume
(EDV) and the end-systolic volume (ESV) increased with more
severe aortic valvular regurgitation, so the graph tends to lean
toward the right (Fig. 6A). In mitral valve regurgitation, the
EDV increased but the ESV decreased with more  severe valvu-
lar regurgitation, so the graph tended to spread to the right
and left (Fig. 6B). When CLVAD treatment was performed in the
case of aortic valvular insufﬁciency, the EDV and ESV increased
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Fig. 7 – Cardiac responses. (A) Cardiac output (CO). (B) Left ventricular stroke work (LV SW). (C) Left ventricular stroke work
(LV SW). (D) left ventricular ejection fraction (LV EF). (E) left ventricular peak pressure (LV PP). (F) Under-valve regurgitation by
the CLVAD and the PLVAD.
AR, aortic regurgitation; CLVAD, continuous left ventricular assist device, MR,  mitral regurgitation; PLVAD, pulsatile left
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ith more  severe regurgitation (Fig. 6C). In the case of mitral
alvular insufﬁciency, the EDV was unaffected by valvular
nsufﬁciency, but the ESV tended to decrease with more  severe
alvular insufﬁciency (Fig. 6D).
With PLVAD treatment, the levels ﬂuctuated in a manner
imilar to those with CLVAD treatment (Fig. 6E and 6F). The
nternal area of the LV volume-pressure graph indicates stroke
ork (SW), which is the amount of work performed in one
entricular pulsation. Fig. 7C shows the SW in the cases of
ortic and mitral valvular insufﬁciency. In Fig. 6, in the case
f aortic valvular insufﬁciency, the internal area of the LV
ressure-volume graph has a high value regardless of LVADtype (Fig. 6A, 6C, and 6E). By contrast, in the case of mitral
valvular insufﬁciency, the internal area of the LV pressure-
volume graph decreased with LVAD treatment (Fig. 6B, 6D, and
6F). Accordingly, in the case of aortic valvular insufﬁciency, the
left ventricle SW (LVSW) did not decrease with LVAD treat-
ment, whereas in the case of mitral valvular insufﬁciency, the
LVSW decreased with LVAD treatment.
Fig. 7 shows the LV cardiac output, SW, and LVPP with-
out LVAD treatment and with CLVAD or PLVAD treatment,
according to the severity of aortic and mitral valve insufﬁ-
ciency. In the case of aortic valvular insufﬁciency, the cardiac
output decreased with more  severe regurgitation when LVAD
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treatment was not performed. In addition, the LVAD blood
ﬂow rate, which contributed to the cardiac output, decreased
with more  severe aortic valve regurgitation (Fig. 7A). The SW
increased with more  severe valvular regurgitation up to a
severity of 6%, and decreased thereafter, regardless of the
LVAD type, and was lowest with PLVAD treatment (Fig. 7C).
LVPP increased with increasing valvular regurgitation sever-
ity. At valvular regurgitation levels of 6–10%, LVPP varied only
slightly according to the severity of regurgitation (Fig. 7E).
In summary, in the case of aortic valvular insufﬁciency,
continuous and pulsatile LVADs improved cardiac output and
reduced mechanical load slightly (Fig. 7A, 7C, and 7E). In
the case of mitral valvular insufﬁciency, the cardiac output
decreased with more  severe valvular regurgitation without
LVAD treatment (3.3 L/min under 10% AR severity), whereas
when CLVAD or PLVAD treatment was performed, a constant
value of ∼5 L/min was observed, regardless of the severity of
regurgitation (Fig. 7 B). The SW increased without LVAD treat-
ment, and decreased with CLVAD or PLVAD treatment (Fig. 7D).
LVPP decreased in all cases with increasing severity of regur-
gitation. The mean value was highest in the absence of LVAD
treatment and lowest in its presence (Fig. 7F).
4.  Discussion
In this study, the effects of valvular insufﬁciency on LVAD func-
tions were numerically investigated by estimating the CLVAD
and PLVAD pumping efﬁciency according to the severity of
aortic and mitral valvular insufﬁciency using an eight com-
partment lumped parameter model. The pumping efﬁciency
was estimated by predicting the hemodynamic responses,
such as LV and aortic blood pressures, LV pressure-volume
curves, cardiac output, LVSW, and LVPP.
When aortic valvular insufﬁciency developed during the
LVAD treatment period, the mean arterial blood pressure and
the cardiac output decreased with increasing regurgitation
severity; but when mitral valvular insufﬁciency developed, the
mean arterial blood pressure and the cardiac output remained
constant, regardless of the regurgitation severity. The anatom-
ical position of the regurgitant valves and cannulation position
of LVAD affect the hemodynamic responses. As the LVAD helps
eject the blood from the LV to the aorta, it is normally intu-
bated from the LV to the aorta. Aortic valvular insufﬁciency
results in the regurgitation of blood from the aorta to the LV.
The blood ejected to the aorta by the LVAD ﬂows back to the
LV and the total cardiac output and blood pressure decrease.
Mitral valvular insufﬁciency results in the regurgitation of
blood from the LV to the LA, so the functions of the LVAD,
which sends blood from the LV to the aorta, are not markedly
affected.
In the case of aortic valvular insufﬁciency, the LV load did
not decrease with LVAD treatment. In the case of mitral valvu-
lar insufﬁciency, however, the LV load decreased with LVAD
treatment. This was due to the LVAD cannulation location
compared to valve location where the regurgitation devel-
oped. In the case of aortic valvular insufﬁciency, the blood
from the LA and the blood regurgitated from the aorta were
mixed to increase the LV blood volume. In addition, the end-
systolic pressure increases to eject the blood (Frank-StarlingIntegr Med Res (  2 0 1 6 ) 22–29
Law; the LV end-systolic pressure is shown in Fig. 7E). The
LV load did not signiﬁcantly decrease with LVAD treatment
due to aortic valve regurgitation. Accordingly, in the case of
aortic valve insufﬁciency, the LVAD functions deteriorated in
terms of ventricular unloading. In the case of mitral valvular
insufﬁciency, the blood ﬂowed in from the LV and then ﬂowed
out to the LA due to regurgitation. A greater volume of blood
ﬂowed into the LA from the LV due to the regurgitated blood,
and the amount of blood in the LA increased abruptly. Accord-
ingly, the work output also increased. Fig. 6 shows the process.
From the viewpoint of energy, this implied that the ventricu-
lar pumping load increased with valvular insufﬁciency. With
LVAD treatment, the aortic ejection of blood was facilitated,
and the LV load decreased. Eventually, in the case of mitral
valvular insufﬁciency, the LVAD could function properly in
terms of ventricular load reduction.
In the LVAD treatment method, the pumping efﬁciency can
be predicted in terms of the decrease in ventricular load and
the maintenance of normal arterial blood pressure. In the case
of mitral valvular insufﬁciency in the simulation, the ventri-
cular load decreased and the arterial blood pressure increased
due to the CLVAD or PLVAD, so the LVAD treatment method was
effective. In the case of aortic valvular insufﬁciency, the ven-
tricular load increased due to CLVAD or PLVAD treatment, and
the arterial blood pressure decreased, which showed that the
LVAD treatment method was ineffective. In the case of mitral
valvular insufﬁciency, which responded well to LVAD treat-
ment, the ventricular load decreased more  signiﬁcantly with
PLVAD treatment than with CLVAD treatment, which showed
that the PLVAD had better pumping efﬁciency than the CLVAD.
This study had several limitations. We used a lumped
parameter model of the cardiovascular system based on the
Windkessel element and the heart was modeled using the
concept of time-varying compliance.17 In order to reduce
modeling complexity, we did not implement the coronary
circulation and nervous short-term regulation of the car-
diovascular system which are implemented in our previous
paper.15 That is because the only short-term blood pressure
regulation by the nervous system without other long-term reg-
ulation would not give us signiﬁcant insight. To simulate the
valve regurgitation caused by mitral and aortic valve insuf-
ﬁciency, only one further route was added to the aortic and
mitral valve compartment for regurgitation, while regurgita-
tion is also inﬂuenced by peripheral parameters. However,
these limitations are not expected to greatly alter the main
ﬁndings of this study.
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